Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

GE HealthCare announced that the NCCN Guidelines for Clinical Oncology now recommend FES PET for systemic staging in patients ...

PET/CT is a useful tool to map out the possible sites where the cancer first originated. PET/CT is a form of hybrid imaging that combines computed tomography (CT), an anatomical imaging ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer ...

This study is using a PET-CT scan after selective internal radiation therapy to find out where in the body the treatment has gone. It is open to people who have cancer that started in the liver or ...

This growth is fueled by the rising prevalence of chronic diseases, increasing demand for non-invasive diagnostic tools, and the integrati ...

Breast cancer remains a leading cause of cancer-related mortality globally, underscoring the critical need for early ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...